Axogen, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US05463X1063
USD
32.85
5.16 (18.65%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Axogen, Inc. stock-summary
stock-summary
Axogen, Inc.
Pharmaceuticals & Biotechnology
AxoGen, Inc. offers surgical solutions for peripheral nerve injuries. The Company provides products and education to improve surgical treatment algorithms for peripheral nerve injuries. Its portfolio of products includes Avance Nerve Graft, AxoGuard Nerve Connector, AxoGuard Nerve Protector and Avive Soft Tissue Membrane. Along with these core surgical products, the Company also offers the AxoTouch Two-Point Discriminator, and AcroVal Neurosensory and Motor Testing System. These evaluation and measurement tools assist healthcare professionals in detecting changes in sensation; assessing return of sensory, grip and pinch function; evaluating treatment interventions, and providing feedback to patients on nerve function. Its portfolio of products is available in the United States, Canada, the United Kingdom and several European and other countries. The Company's products are used by surgeons during surgical interventions to repair a range of nerve injuries throughout the body.
Company Coordinates stock-summary
Company Details
13631 Progress Blvd Ste 400 , ALACHUA FL : 32615-9409
stock-summary
Tel: 1 386 4626817
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 51 Schemes (26.93%)

Foreign Institutions

Held by 63 Foreign Institutions (10.93%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Ms. Karen Zaderej
Chairman of the Board, President, Chief Executive Officer
Ms. Amy Wendell
Lead Independent Director
Mr. Gregory Freitag
Director
Mr. Paul Thomas
Director
Mr. Quentin Blackford
Independent Director
Dr. Mark Gold
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
57 Million
(Quarterly Results - Jun 2025)
Net Profit:
1 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 738 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.13

stock-summary
Return on Equity

-4.49%

stock-summary
Price to Book

6.57